Stock of the Day

Today's Trend

CRISPR Therapeutics AG (NASDAQ: CRSP) shares have increased recently as analysts highlighted substantial potential upside and investors looked ahead to clinical data for the company’s gene-editing pipeline. The main catalysts are analyst support, the upcoming CTX310 data presentation, and continued progress in commercializing its gene-editing platform.

• Analyst price targets remain well above the current trading level. BofA trimmed its target modestly to $81 from $82 while maintaining a Buy rating. Separately, Citi sees approximately 60% upside, although that potential depends on three key developments going as planned. BofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy Rating Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
• CRISPR Therapeutics will present late-breaking Phase 1b data for CTX310 at the American Heart Association Scientific Sessions on November 9. The in vivo CRISPR/Cas9 therapy targets ANGPTL3 for severe hypertriglyceridemia, making the presentation a potentially important clinical catalyst. CRISPR Therapeutics to Present Late-Breaking Data at the AHA Scientific Sessions 2026
• Wall Street’s overall view is Moderate Buy. The consensus target price is $67.94, supported by two Strong Buy, nine Buy, six Hold, and one Sell rating. This indicates generally favorable sentiment, but also meaningful disagreement about the company’s valuation and clinical risk. CRISPR Therapeutics Stock Now Rated Moderate Buy by Wall Street Analysts
• General Counsel James Kasinger sold 1,990 shares for approximately $119,480. The transaction reduced his holdings by 2.06%, which could weigh modestly on sentiment, though he retained 94,784 shares and the sale does not by itself indicate a change in company fundamentals. CRISPR Therapeutics General Counsel Sells Stock